Guy Cavet

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/11437135/publications.pdf

Version: 2024-02-01

394421 713466 3,073 21 19 21 citations h-index g-index papers 22 22 22 5431 all docs docs citations times ranked citing authors

#	Article	IF	CITATIONS
1	Death-receptor O-glycosylation controls tumor-cell sensitivity to the proapoptotic ligand Apo2L/TRAIL. Nature Medicine, 2007, 13, 1070-1077.	30.7	542
2	Epithelial versus Mesenchymal Phenotype Determines <i>In vitro</i> Sensitivity and Predicts Clinical Activity of Erlotinib in Lung Cancer Patients. Clinical Cancer Research, 2005, 11, 8686-8698.	7.0	485
3	<i>In vivo</i> Antitumor Activity of MEK and Phosphatidylinositol 3-Kinase Inhibitors in Basal-Like Breast Cancer Models. Clinical Cancer Research, 2009, 15, 4649-4664.	7.0	434
4	Genetic Alterations and Oncogenic Pathways Associated with Breast Cancer Subtypes. Molecular Cancer Research, 2009, 7, 511-522.	3.4	201
5	Longitudinal Analysis of the Human B Cell Response to Ebola Virus Infection. Cell, 2019, 177, 1566-1582.e17.	28.9	153
6	Validation of a novel multibiomarker test to assess rheumatoid arthritis disease activity. Arthritis Care and Research, 2012, 64, 1794-1803.	3.4	149
7	Efficacy and safety of mavrilimumab in subjects with rheumatoid arthritis. Annals of the Rheumatic Diseases, 2013, 72, 1445-1452.	0.9	149
8	Development of a Multi-Biomarker Disease Activity Test for Rheumatoid Arthritis. PLoS ONE, 2013, 8, e60635.	2.5	146
9	Performance of a multi-biomarker score measuring rheumatoid arthritis disease activity in the CAMERA tight control study. Annals of the Rheumatic Diseases, 2012, 71, 1692-1697.	0.9	107
10	Functional Genomics Identifies ABCC3 as a Mediator of Taxane Resistance in HER2-Amplified Breast Cancer. Cancer Research, 2008, 68, 5380-5389.	0.9	102
11	Non-progressing cancer patients have persistent B cell responses expressing shared antibody paratopes that target public tumor antigens. Clinical Immunology, 2018, 187, 37-45.	3.2	86
12	Characterization of a multiplex, 12-biomarker test for rheumatoid arthritis. Journal of Pharmaceutical and Biomedical Analysis, 2012, 70, 415-424.	2.8	82
13	A multi-biomarker score measures rheumatoid arthritis disease activity in the BeSt study. Rheumatology, 2013, 52, 1202-1207.	1.9	79
14	Molecular predictors of response to a humanized anti–insulin-like growth factor-l receptor monoclonal antibody in breast and colorectal cancer. Molecular Cancer Therapeutics, 2009, 8, 2110-2121.	4.1	78
15	Repertoire Builder: high-throughput structural modeling of B and T cell receptors. Molecular Systems Design and Engineering, 2019, 4, 761-768.	3.4	62
16	An evaluation of molecular and clinical remission in rheumatoid arthritis by assessing radiographic progression. Rheumatology, 2013, 52, 839-846.	1.9	59
17	Comment on "The Consensus Coding Sequences of Human Breast and Colorectal Cancers". Science, 2007, 317, 1500-1500.	12.6	53
18	Inferring the functional effects of mutation through clusters of mutations in homologous proteins. Human Mutation, 2010, 31, 264-271.	2.5	48

#	Article	IF	CITATIONS
19	Impact of a multi-biomarker disease activity test on rheumatoid arthritis treatment decisions and therapy use. Current Medical Research and Opinion, 2013, 29, 85-92.	1.9	24
20	A multi-biomarker disease activity score tracks clinical response consistently in patients with rheumatoid arthritis treated with different anti-tumor necrosis factor therapies: A retrospective observational study. Modern Rheumatology, 2015, 25, 344-349.	1.8	17
21	Distinct clonal evolution of B-cells in HIV controllers with neutralizing antibody breadth. ELife, 2021, 10, .	6.0	16